Sandoz announced on Friday that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013.
Sandoz announced on Friday that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013.
According to a statement from Stefan Hendriks, global head of biopharmaceuticals at Sandoz, "We appreciate the important conversations with the FDA, which have provided specific requirements for our potential US biosimilar rituximab, but believe the patient and marketplace needs in the [United States] will be satisfied before we can generate the data required.” Hendricks added that Sandoz would now focus on the biosimilars in its pipeline that “can best meet rapidly evolving patient and healthcare system needs.”
In May 2018, Sandoz announced that it had received a Complete Response Letter from the FDA for the proposed biosimilar. Sandoz had sought FDA approval for all indications of the brand-name Rituxan.
While the FDA had requested additional data from Sandoz on the product, the biosimilar has been approved in the European Union since June 2017, where it is sold as Rixathon. The data package leading to European authorization included data from the ASSIST-RA study, which demonstrated equivalent pharmacokinetic and pharmacodynamic profiles of the biosimilar and its reference, with no clinically meaningful differences in safety, tolerability, or immunogenicity in patients with rheumatoid arthritis (RA). Also included were data from the ASSIST-FL study, a phase 3 confirmatory study in which the biosimilar and its reference showed equivalent overall response rate and comparable safety at 6 months in patients with follicular lymphoma.
Further data from a randomized, double-blind, parallel-group study conducted at 28 centers in the United States and 26 centers in the European Union has demonstrated that switching to the biosimilar from the reference rituximab is safe in patients with active RA.
Sandoz’s change of course means that there will likely be only 1 biosimilar rituximab product available to US patients in the foreseeable future; Celltrion’s CT-P10 recently received a unanimous recommendation from the FDA’s Oncologic Drugs Advisory Committee and is awaiting a final regulatory approval.
However, Celltrion, because of issues related to patents on the originator drug, is only seeking FDA approval for the treatment of non-Hodgkin lymphoma, and is not seeking any indication for the treatment of inflammatory diseases such as RA.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.